Summer’s over. A new school year is in session, and it’s time to get back to business. Market Pathways’ editors Steve Levin and David Filmore talk about global medtech policy issues they’ll be paying attention to this fall. We start with the FDA user reauthorization nail-biter in Congress, and then talk about what to expect from CMS on a new medtech coverage pathway. The ever-present tribulations in the EU come up, of course, and we finish with a quick check-in on India and China.
nail-biter in Congress (1:47)
a new medtech coverage pathway (21:54)
tribulations in the EU come up (36:04)
check-in on India and China (46:50)
Here’s some Market Pathways content referenced in this episode:
Market Pathways Podcast episodes:
Jeff Shuren on FDA-sponsor interactions: Where they’ve been and where they’re going https://apple.co/3QY3n89
Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan https://apple.co/3LqhRMK
Market Pathways’ articles:
Germany and France Push to Move MDR Deadlines to Avoid Crisis https://bit.ly/3xCC5NE
